ERNA Stock Analysis: Buy, Sell, or Hold?
ERNA - Ernexa Therapeutics Inc. Common Stock
$0.92
-0.32 (-25.80%)
▼
5d:
-20.68%
30d:
-20.68%
90d:
-51.06%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 11, 2026
Get Alerted When ERNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ERNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ERNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ERNA is currently trading at $0.92, which is considered oversold relative to its 30-day fair value range of $1.13 to $1.29.
Technical Outlook: Technically, ERNA is showing sideways momentum. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 25.8% recently.
Market Sentiment: ERNA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+226.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ERNA is showing sideways momentum. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 25.8% recently.
Market Sentiment: ERNA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+226.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.13 -
$1.29
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-25.8%)
- BULLISH: Trading 226.1% below Wall St target ($3.00)
- CAUTION: 5-day price weakness (-20.7%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$1.13 -
$1.29
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.92
Resistance Level
$1.28
Current Trend
Sideways
Fundamental Context
Wall Street Target
$3.00
(+226.1%)
Revenue Growth (YoY)
-94.1%
Last updated: February 03, 2026 6:45 PM ET
Data refreshes hourly during market hours. Next update: 7:45 PM
Data refreshes hourly during market hours. Next update: 7:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$477 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 51 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$514 | 61 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 61 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 53 HOLD |
